Advances in Therapy

, Volume 23, Issue 4, pp 582–600 | Cite as

Delayed P300 latency correlates with abnormal Test of Variables of Attention (TOVA) in adults and predicts early cognitive decline in a clinical setting

  • Eric R. Braverman
  • Thomas J. H. Chen
  • John Schoolfield
  • Manuel Martinez-Pons
  • Vanessa Arcuri
  • Michael Varshavskiy
  • Cory A. Gordon
  • Julie Mengucci
  • Seth H. Blum
  • Brian Meshkin
  • Bernard W. Downs
  • Kenneth Blum

Abstract

Delayed P300 latency identifies dementia better than the Mini-Mental Status Exam and, in some cases, the Wechsler Memory Scale (WMS-III). The purpose of this study was to determine whether the outcome of an objective Test of Variables of Attention (TOVA) correlates with the findings of an electrophysiologic test—P300 latency—in patients 40 y of age or older. Adult attention deficit disorder may be an important premorbid marker of memory dysfunction or dementia. In males, the means for P300 latency and age-adjusted P300 latency were significantly greater for patients classified as SD-BL (significantly deviant or borderline: TOVA < -1.0) than for those categorized as normal (TOVA≥0) for attention failure (ie, omissions [P<.010] and commissions [P<.005]) but not for response time or for variability. Males with >2 SD-BL quarters had significantly delayed P300 latency and age-adjusted P300 latency compared with males who had 0 SD-BL quarters (P<.020) and 1 SD-BL quarter (P<.005). In females, the means for P300 latency and age-adjusted P300 latency were significantly delayed for those grouped as SD-BL than for those labeled normal for response time (P<.001) and variability (P<.010), but not for omissions or for commissions. Females with >2 SD-BL quarters had significantly delayed P300 latency and age-adjusted P300 latency compared with females who had 0 SD-BL quarters (P<.005) and 1 SD-BL quarter (P<.010). Results suggest that TOVA abnormalities may be an indicator of delayed P300 and attention disorder. Recent research correlates TOVA abnormalities with impaired WMS scores of early dementia. Coupling of TOVA assessment findings with results of P300, Mini-Mental Status Exam, and WMS-III may allow for enhanced accuracy in the diagnosis and evaluation of the complex pathway of failing attention, memory, and cognition that leads to dementia.

Keywords

P300 TOVA Wechsler Memory Scale attention complaints QEEG 

References

  1. 1.
    Braverman ER, Blum K. P300 (latency) event-related potential: an accurate predictor of memory impairment.Clin Electroencephalogr. 2003;34:124–139.PubMedGoogle Scholar
  2. 2.
    Johnstone B, Hogg JR, Schopp LH, Kapila C, Edwards S. Neuropsychological deficit profiles in senile dementia of the Alzheimer’s type.Arch Clin Neuropsychol. 2002;17:273–281.PubMedCrossRefGoogle Scholar
  3. 3.
    Arnaiz E, Almkvist O. Neuropsychological features of mild cognitive impairment and preclinical Alzheimer’s disease.Acta Neurol Scand Suppl. 2003;179:34–41.PubMedCrossRefGoogle Scholar
  4. 4.
    Boone KB, Miller BL, Swartz R, Lu P, Lee A. Relationship between positive and negative symptoms and neuropsychological scores in frontotemporal dementia and Alzheimer’s disease.J Int Neuropsychol Soc. 2003;9:698–709.PubMedCrossRefGoogle Scholar
  5. 5.
    Jackson GR, Owsley C. Visual dysfunction, neurodegenerative diseases, and aging.Neurol Clin. 2003;21:709–728.PubMedCrossRefGoogle Scholar
  6. 6.
    Knox MR, Lacritz LH, Chandler MJ, Munro Cullum C. Association between Dementia Rating Scale performance and neurocognitive domains in Alzheimer’s disease.Clin Neuropsychol. 2003; 17:216–219.PubMedGoogle Scholar
  7. 7.
    Tales A, Muir J, Jones R, Bayer A, Snowden RJ. The effects of saliency and task difficulty on visual search performance in ageing and Alzheimer’s disease.Neuropsychologia. 2004;42:335–345.PubMedCrossRefGoogle Scholar
  8. 8.
    Sheridan PL, Solomont J, Kowall N, Hausdorff JM. Influence of executive function on locomotor function: divided attention increases gait variability in Alzheimer’s disease.J Am Geriatr Soc. 2003;51:1633–1637.PubMedCrossRefGoogle Scholar
  9. 9.
    Bennett DA. Update on mild cognitive impairment.Curr Neurol Neurosci Rep. 2003;3:379–384.PubMedCrossRefGoogle Scholar
  10. 10.
    Papagno C, Allegra A, Cardaci M. Time estimation in Alzheimer’s disease and the role of the central executive.Brain Cogn. 2004;54:18–23.PubMedCrossRefGoogle Scholar
  11. 11.
    Braverman ER, Chen TJH, Rayannavar A, et al. Test of Variables of Attention (TOVA): an accurate predictor of early attentional complaints in a clinical setting.J Psychiatr Res. 2006 (submitted).Google Scholar
  12. 12.
    Grundman M, Petersen RC, Ferris SH, et al. Alzheimer’s disease cooperative study: mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials.Arch Neurol. 2004;61:59–66.PubMedCrossRefGoogle Scholar
  13. 13.
    Knopman DS, Boeve BF, Petersen RC. Essentials of the proper diagnoses of mild cognitive impairment, dementia, and major subtypes of dementia.Mayo Clin Proc. 2003;78:1290–1308.PubMedCrossRefGoogle Scholar
  14. 14.
    Petersen RC. Aging, mild cognitive impairment, and Alzheimer’s disease.Neurol Clin. 2000; 18:789–806.PubMedCrossRefGoogle Scholar
  15. 15.
    Petersen RC. Mild cognitive impairment: transition between aging and Alzheimer’s disease.Neurologia. 2000;15:93–101.PubMedCrossRefGoogle Scholar
  16. 16.
    Morris JC, Storandt M, Miller JP, et al. Mild cognitive impairment represents early-stage Alzheimer disease.Arch Neurol. 2001;58:397–405.PubMedCrossRefGoogle Scholar
  17. 17.
    Storandt M, Grant EA, Miller JP, Morris JC. Rates of progression in mild cognitive impairment and early Alzheimer’s disease.Neurology. 2002;59:1034–1041.PubMedGoogle Scholar
  18. 18.
    McCracken J. Attention-deficit disorders. In: Sadock BJ, Sadock VA, eds.Kaplan and Sadock’s Comprehensive Textbook of Psychiatry. 7th ed. Philadelphia, Pa: Lippincott Williams and Wilkins; 2000:2679–2685.Google Scholar
  19. 19.
    McCracken J. Attention-deficit disorders. In: Sadock BJ, Sadock VA, eds.Kaplan and Sadock’s Comprehensive Textbook of Psychiatry. 7th ed. Philadelphia, Pa: Lippincott Williams and Wilkins; 2000:2688–2692.Google Scholar
  20. 20.
    Milberger S, Biederman J, Faraone SV, Murphy J, Tsuang MT. Attention deficit hyperactivity disorder and comorbid disorders: issues of overlapping symptoms.Am J Psychiatry. 1995;152: 1793–1799.PubMedGoogle Scholar
  21. 21.
    Hinshaw SP. Academic underachievement, attention deficits, and aggression: comorbidity and implications for intervention.J Consult Clin Psychol. 1992;60:893–903.PubMedCrossRefGoogle Scholar
  22. 22.
    Silver LB. The relationship between learning disabilities, hyperactivity, distractibility, and behavioral problems: a clinical analysis.J Am Acad Child Psychiatry. 1981;20:385–397.PubMedCrossRefGoogle Scholar
  23. 23.
    Silverstein ML, Mavrolefteros G, Turnbull A. Premorbid factors in relation to motor, memory, and executive functions deficits in adult schizophrenia.Schizophr Res. 2003;61:271–280.PubMedCrossRefGoogle Scholar
  24. 24.
    Riordan HJ, Flashman LA, Saykin AJ, Frutiger SA, Carroll KE, Huey L. Neuropsychological correlates of methylphenidate treatment in adult ADHD with and without depression.Arch Clin Neuropsychol. 1999;14:217–233.PubMedCrossRefGoogle Scholar
  25. 25.
    Harmer CJ, Clark L, Grayson L, Goodwin GM. Sustained attention deficit in bipolar disorder is not a working memory impairment in disguise.Neuropsychologia. 2002;40:1586–1590.PubMedCrossRefGoogle Scholar
  26. 26.
    Katz LJ, Wood DS, Goldstein G, Auchenbach RC, Geckle M. The utility of neuropsychological tests in evaluation of attention-deficit/hyperactivity disorder (ADHD) versus depression in adults.Assessment. 1998;5:45–52.PubMedCrossRefGoogle Scholar
  27. 27.
    van der Feltz-Cornelis CM. Intractable obsessive-compulsive disorder: comorbidity with unrecognized adult attention-deficit hyperactivity disorder?J Nerv Ment Dis. 1999;187:243–245.PubMedCrossRefGoogle Scholar
  28. 28.
    Johnson DE, Epstein JN, Waid LR, Latham PK, Voronin KE, Anton RF. Neuropsychological performance deficits in adults with attention deficit/hyperactivity disorder.Arch Clin Neuropsychol. 2001;16:587–604.PubMedCrossRefGoogle Scholar
  29. 29.
    Ossmann JM, Mulligan NW. Inhibition and attention deficit hyperactivity disorder in adults.Am J Psychol. 2003;116:35–50.PubMedCrossRefGoogle Scholar
  30. 30.
    Estevez-Gonzalez A, Garcia-Sanchez C, Boltes A, et al. Sustained attention in the preclinical phase of Alzheimer’s disease.Rev Neurol. 2003;36:829–832.PubMedGoogle Scholar
  31. 31.
    King JA, Barkley RA, Delville Y, Ferris CF. Early androgen treatment decreases cognitive function and catecholamine innervation in an animal model of ADHD.Behav Brain Res. 2000;107:35–43.PubMedCrossRefGoogle Scholar
  32. 32.
    Mihailescu S, Drucker-Colin R. Nicotine, brain nicotinic receptors, and neuropsychiatric disorders.Arch Med Res. 2000;31:131–144.PubMedCrossRefGoogle Scholar
  33. 33.
    Adesman AR, Altshuler LA, Lipkin PH, Walco GA. Otitis media in children with learning disabilities and in children with attention deficit disorder with hyperactivity.Pediatrics. 1990; 85(3 Pt 2):442–446.PubMedGoogle Scholar
  34. 34.
    Van der Werf YD, Scheltens P, Lindeboom J, et al. Deficits of memory, executive functioning and attention following infarction in the thalamus: a study of 22 cases with localised lesions.Neuropsychologia. 2003;41:1330–1344.PubMedCrossRefGoogle Scholar
  35. 35.
    Channon S, Pratt P, Robertson MM. Executive function, memory, and learning in Tourette’s syndrome.Neuropsychology. 2003;17:247–254.PubMedCrossRefGoogle Scholar
  36. 36.
    Traykov L, Baudic S, Thibaudet MC, Rigaud AS, Smagghe A, Boller F. Neuropsychological deficit in early subcortical vascular dementia: comparison to Alzheimer’s disease.Dement Geriatr Cogn Disord. 2002;14:26–32.PubMedCrossRefGoogle Scholar
  37. 37.
    Wester K, Irvine DR, Hugdahl K. Auditory laterality and attentional deficits after thalamic haemorrhage.J Neurol. 2001;248:676–683.PubMedCrossRefGoogle Scholar
  38. 38.
    Nag S, Rao SL. Remediation of attention deficits in head injury.Neurol India. 1999;47:32–39.PubMedGoogle Scholar
  39. 39.
    Naumann A, Bierbrauer J, Przuntek H, Daum I. Attentive and preattentive processing in narcolepsy as revealed by event-related potentials (ERPs).Neuroreport. 2001;12:2807–2811.PubMedCrossRefGoogle Scholar
  40. 40.
    Piras MR, Magnano I, Canu ED, et al. Longitudinal study of cognitive dysfunction in multiple sclerosis: neuropsychological, neuroradiological, and neurophysiological findings.J Neurol Neurosurg Psychiatry. 2003;74:878–885.PubMedCrossRefGoogle Scholar
  41. 41.
    Shahar E, Shinawi M. Neurocristopathies presenting with neurologic abnormalities associated with Hirschsprung’s disease.Pediatr Neurol. 2003;28:385–391.PubMedCrossRefGoogle Scholar
  42. 42.
    Lahat E, Broide E, Leshem M, Evans S, Scapa E. Prevalence of celiac antibodies in children with neurologic disorders.Pediatr Neurol. 2000;22:393–396.PubMedCrossRefGoogle Scholar
  43. 43.
    Fallon BA, Kochevar JM, Gaito A, Nields JA. The underdiagnosis of neuropsychiatric Lyme disease in children and adults.Psychiatr Clin North Am. 1998;21:693–703, viii.PubMedCrossRefGoogle Scholar
  44. 44.
    Stein MA, Weiss RE. Thyroid function tests and neurocognitive functioning in children referred for attention deficit/hyperactivity disorder.Psychoneuroendocrinology. 2003;28:304–316.PubMedCrossRefGoogle Scholar
  45. 45.
    Saxby BK, Harrington F, McKeith IG, Wesnes K, Ford GA. Effects of hypertension on attention, memory, and executive function in older adults.Health Psychol. 2003;22:587–591.PubMedCrossRefGoogle Scholar
  46. 46.
    Trojano L, Antonelli Incalzi R, Acanfora D, et al. Congestive heart failure Italian study investigators. Cognitive impairment: a key feature of congestive heart failure in the elderly.J Neurol. 2003;250: 1456–1463.PubMedCrossRefGoogle Scholar
  47. 47.
    Antonelli Incalzi R, Marra C, Giordano A, et al. Cognitive impairment in chronic obstructive pulmonary disease—a neuropsychological and spect study.J Neurol. 2003;250:325–332.CrossRefGoogle Scholar
  48. 48.
    Coker LH, Shumaker SA. Type 2 diabetes mellitus and cognition: an understudied issue in women’s health.J Psychosom Res. 2003;54:129–139.PubMedCrossRefGoogle Scholar
  49. 49.
    Gayton WF, Bailey C, Wagner A, Hardesty VA. Relationship between childhood hyperactivity and accident proneness.Percept Mot Skills. 1986;63:801–802.PubMedGoogle Scholar
  50. 50.
    Barkley RA. Advancing age, declining ADHD.Am J Psychiatry. 1997;154:1323–1325.PubMedGoogle Scholar
  51. 51.
    Hansen C, Weiss D, Last CG. ADHD boys in young adulthood: psychosocial adjustment.J Am Acad Child Adolesc Psychiatry. 1999;38:165–171.PubMedCrossRefGoogle Scholar
  52. 52.
    Swensen AR, Birnbaum HG, Secnik K, Marynchenko M, Greenberg P, Claxton A. Attention-deficit/hyperactivity disorder: increased costs for patients and their families.J Am Acad Child Adolesc Psychiatry. 2003;42:1415–1423.PubMedCrossRefGoogle Scholar
  53. 53.
    Woodward LJ, Fergusson DM, Horwood LJ. Driving outcomes of young people with attentional difficulties in adolescence.J Am Acad Child Adolesc Psychiatry. 2000;39:627–634.PubMedCrossRefGoogle Scholar
  54. 54.
    Green M, Wong M, Atkins D, et al. Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Council on Scientific Affairs, American Medical Association. Technical Review No. 3. Rockville, Md: Agency for Health Care Policy and Research; 1999. AHCPR Publication No. 99-0050.Google Scholar
  55. 55.
    Szatmari P, Offord DR, Boyle MH. Correlates, associated impairments and patterns of service utilization of children with attention deficit disorder: findings from the Ontario Child Health Study.J Child Psychol Psychiatry. 1989;30:205–217.PubMedCrossRefGoogle Scholar
  56. 56.
    Blum K, Braverman ER, Holder JM, et al. Reward deficiency syndrome: a biogenetic model for the diagnosis and treatment of impulsive, addictive, and compulsive behaviors.J Psychoactive Drugs. 2000;32(suppl i–iv):1–112.Google Scholar
  57. 57.
    Noble EP, Berman SM, Ozkaragoz TZ, Ritchie T. Prolonged P300 latency in children with the D2 dopamine receptor A1 allele.Am J Hum Genet. 1994;54:658–668.PubMedGoogle Scholar
  58. 58.
    Kirley A, Lowe N, Hawi Z, et al. Association of the 480 bp DAT1 allele with methylphenidate response in a sample of Irish children with ADHD.Am J Med Genet B Neuropsychiatr Genet. 2003;121:50–54.PubMedCrossRefGoogle Scholar
  59. 59.
    Manor I, Tyano S, Eisenberg J, et al. The short DRD4 repeats confer risk to attention deficit hyperactivity disorder in a family-based design and impair performance on a continuous performance test (TOVA).Mol Psychiatry. 2002;7:790–794.PubMedCrossRefGoogle Scholar
  60. 60.
    Conners CK. A teacher rating scale for use in drug studies with children.Am J Psychiatry. 1969; 126:884–888.PubMedGoogle Scholar
  61. 61.
    Forbes GB. Clinical utility of the test of variables of attention (Tova) in the diagnosis of attention-deficit/hyperactivity disorder.J Clin Psychol. 1998;54:461–476.PubMedCrossRefGoogle Scholar
  62. 62.
    Monastra VJ, Lubar JF, Linden M. The development of a quantitative electroencephalographic scanning process for attention deficit-hyperactivity disorder: reliability and validity studies.Neuropsychology. 2001;15:136–144.PubMedCrossRefGoogle Scholar
  63. 63.
    Lindau M, Jelic V, Johansson SE, Anderson C, Wahlund LO, Almkvist O. Quantitative EEG abnormalities and cognitive dysfunctions in frontotemporal dementia and dementia disease.Demeter Geriatr Cogn Disord. 2003;15:106–114.CrossRefGoogle Scholar
  64. 64.
    Rodriguez G, Vitali P, Canfora M, et al. Quantitative EEG and perfusional single photon emission computed tomography correlation during long-term donepezil therapy in Alzheimer’s disease.Clin Neurophysiol. 2004;115:39–49.PubMedCrossRefGoogle Scholar
  65. 65.
    McDaniel MA, Maier SF, Einstein GO. “Brain-specific” nutrients: a memory cure?Nutrition. 2003;19:957–975.PubMedCrossRefGoogle Scholar
  66. 66.
    Naumann A, Bierbrauer J, Przuntek H, Daum I. Attentive and preattentive processing in narcolepsy as revealed by event-related potentials (ERPs).Neuroreport. 2001;12:2807–2811.PubMedCrossRefGoogle Scholar
  67. 67.
    Burkhardt MS, Foster JK, Clarnette RM, et al. Interaction between testosterone and apolipoprotein E epsilon 4 status on cognition in healthy older men.J Clin Endocrinol Metab. 2006;91:1168–1172.PubMedCrossRefGoogle Scholar
  68. 68.
    Braverman ER, Blum Chen, Marinez-Pons M, Arcuria V, Meshkin B. Low human plasma levels of sex hormones and human growth factor(s) correlate to cognitive decline marked by prolonged P300 latency as a function of gender in a clinical setting: a paradigm shift. Presented at: Endocrine Society 88th Annual Meeting; June 24–27, 2006; Boston, Mass.Google Scholar
  69. 69.
    Conners CK. Rating scales in attention-deficit/hyperactivity disorder: use in assessment and treatment monitoring.J Clin Psychiatry. 1998;59(suppl 7):24–30.PubMedGoogle Scholar
  70. 70.
    Rasmussen NH. Diagnosis of attention deficit disorders, hyperactivity disorders and DAMP in children.Ugeskr Laeger. 2002;164:4631–4636.PubMedGoogle Scholar

Copyright information

© Springer Science and Business Media and LLC 2006

Authors and Affiliations

  • Eric R. Braverman
    • 1
  • Thomas J. H. Chen
    • 2
    • 3
  • John Schoolfield
    • 4
  • Manuel Martinez-Pons
    • 5
  • Vanessa Arcuri
    • 1
  • Michael Varshavskiy
    • 1
  • Cory A. Gordon
    • 6
  • Julie Mengucci
    • 6
  • Seth H. Blum
    • 6
  • Brian Meshkin
    • 7
  • Bernard W. Downs
    • 8
  • Kenneth Blum
    • 1
    • 7
    • 9
  1. 1.PATH Research FoundationNew York
  2. 2.Chang Jung Christian UniversityTainanTaiwan
  3. 3.Changhua Christian HospitalChanghuaTaiwan
  4. 4.Department of Academic Informatics ServicesUniversity of Texas Health Science CenterSan Antonio
  5. 5.School of EducationBrooklyn College of the City University of New YorkNew York
  6. 6.Synaptamine, Inc.San Antonio
  7. 7.Salugen, Inc.San Diego
  8. 8.Allied Nutraceutical ResearchLederach
  9. 9.Department of Physiology & PharmacologyWake Forest University School of MedicineWinston-SalemUSA

Personalised recommendations